Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 693.35

-0.2%

Nov 14 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

Recommended by:

DewDiligence_on_SI

To: DewDiligence_on_SI who wrote (2548)	11/6/2018 10:28:05 AM
From: Miljenko Zuanic	1 Recommendation of 3559

On Q about future Eylea market dynamic, Schleifer mentioned continuous 10-15% growth in anti-VEGF iv. I think that it is in line with expected. EU decline in 3Q v 2Q may be due to summer months related vocations, that differ from US market. Maybe also due to higher rebate, from Lucentis competition. Positive from cc, is 1L NSCLC mono v chemo trials, that increase # from 300 to +700! It is ex-US trial (+150 sites), and with primary PFS it may be base for accelerated approval (at least ex-US)!

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next